EL-PFDD Meeting

View the recording of the Externally-Led Patient Focused Drug Development Meeting for Polyglutamine Ataxias live-stream from September 25, 2020.

What is an Externally-Led Patient-Focused Drug Development Meeting?

An Externally-Led Patient-Focused Drug Development (EL-PFDD) meeting gives the FDA and other key stakeholders, including medical product developers, health care providers, and federal partners an important opportunity to hear directly from patients, their families, caregivers, and patient advocates about the symptoms that matter most to them, the impact the disease has on patients’ daily lives, and patients’ experiences with currently available treatments. This input can inform FDA’s decisions and oversight both during drug development and during review of a marketing application. EL-PFDD meetings strengthen understanding of disease and treatment burden. They also raise awareness and channel engagement within the patient community.

Learn More

Watch our informational webinar to learn more about what this meeting means, how the process will work, and how you can get involved. 

Print Friendly, PDF & Email

Leave a Reply

Your email address will not be published. Required fields are marked *

Name *

Translate »

Join NAF

Become a member for FREE!
It only takes a few moments.

Sign up today to receive:

  • News and research opportunities about your specific type of Ataxia as they become available
  • Early access to free webinars
  • eNewsletter and Generations publications

Your gift to Ataxia research DOUBLED through December 31st

Contributions to the Annual Research Drive help NAF fund the very best Ataxia research. An anonymous donor will match every dollar donated during this campaign, up to $50,000.

Your donation means more Ataxia research! Thank you for supporting NAF as we seek effective treatments for Ataxia.

Thank you so much!